Reality of the ASPIRE Study
Video Categories: ASH 2014
Ajai Chari, MD, at the Mount Sinai School of Medicine in New York, deliberates on the results of the ASPIRE study as the most important thing to come out of ASH for the myeloma community. He mentions that although the study has very positive indications, the therapy isn’t really appropriate for a large portion of the myeloma population. The most practice changing piece of the study may be regarding the proven safety of carfilzomib.
November 24, 2014
Dr. Gary Palmer discusses the different profile of tumors and how to make findings as general as possible to better treat the patient.
January 20, 2016
Dr Wainberg and Dr Gerson review the characteristics of these stem cells, what some of the medicines are doing right now, and some of the expectations in future clinical trials.